• A small group of viruses and one bacterium are clearly linked to human cancers.
• In animals, many DNA and RNA viruses can cause tumors. → Memory: “Animals: many → Humans: few.”
• In humans, only a handful of viruses and Helicobacter pylori (a bacterium) are established carcinogens.
• Helicobacter pylori infection of the stomach is linked to gastric adenocarcinoma and gastric MALT lymphoma. → Memory: “H. pylori = Hot stomach cancer.”

2. HTLV-1 — The Only Proven Human Oncogenic Retrovirus

2.1 Basic Identity

• Name: Human T-cell leukemia virus type 1 (HTLV-1). → Memory: “HTLV-1 = Human retro-oncovirus #1.”
• Cancer: Causes Adult T-cell leukemia/lymphoma (ATLL). → Memory: “HTLV-1 = Adult T-cells.”
• Primary target cell: CD4+ T cells (same “door” HIV uses). → Memory: “CD4 = Door for HTLV-1.”

2.2 Epidemiology and Transmission

• Endemic regions:
• Japan
• Caribbean
• South America
• Africa
• Plus sporadic cases in the USA → Memory: “J-CASA” (Japan, Caribbean, South America, Africa).
• Global burden: about 15–20 million infected worldwide. → Memory: “20 million silent carriers.”
• Transmission routes:
• Sexual contact
• Blood exposure (transfusions, needles)
• Breastfeeding → Memory: “3 doors: Sex, Blood, Milk.”
• Only about 3–5% of infected individuals develop ATLL, after a long latency of about 40–60 years. → Memory: “Few get sick, but decades later.”

2.3 Viral Integration and Oncogene Status

• HTLV-1 does not carry a classic viral oncogene.
• There is no consistent pattern of integration near the same proto-oncogene across patients. → Memory: “No stowaway oncogene.”
• In different patients, the integration site is random, but within a single tumor clone, the integration site is identical (clonal). → This shows the virus was already present when the malignant clone was formed. → Memory: “Same site in clone = scene of crime.”

2.4 Key Oncogenic Factor: Tax

• The crucial HTLV-1 regulatory gene in cancer is tax. → Memory: “Tax collects cancer debt.”
• Tax protein functions (3 major jobs):
1. Boosts viral RNA synthesis → helps the virus replicate.
2. Reprograms host transcription → alters which host genes are turned on or off.
3. Hijacks host signaling pathways → rewires growth/survival signals. → Memory: “Tax = virus control + host control.”

2.4.1 Pro-Growth and Survival Signaling

• Activates PI3K pathway → promotes growth and survival.
• Alters the cell cycle:
• Increases cyclin D
• Decreases CDK inhibitors
• Pushes cells through G1/S transition.
• Activates NF-κB, a pro-survival transcription factor. → Memory: “Growth promoter + cell-cycle pusher + NF-κB activator.”

2.4.2 Genomic Instability

• Tax impairs DNA repair and cell-cycle checkpoints.
• Leads to aneuploidy (abnormal chromosome numbers). → Memory: “Tax breaks the DNA police.”

2.5 Stepwise Path to ATLL

1. Initial infection of CD4+ T cells.
2. Polyclonal T-cell expansion driven by Tax (many clones proliferate).
3. Accumulation of mutations and genomic instability in these cells.
4. Common driver themes: upregulated T-cell receptor (TCR) signaling and NF-κB activation.
5. Eventually, a single monoclonal T-cell clone dominates → Adult T-cell leukemia/lymphoma. → Memory: “Poly → Mutate → Mono → Malignant.” → Memory: “Final push = TCR + NF-κB ON.”

🧠 EXAM REFLEX BLOCK — Oncogenic Microbes & HTLV-1

🔑 Big-Picture Gate (1-line entry reflex)

• Animals: many DNA & RNA viruses cause tumors
• Humans: few viruses + ONE bacterium (H. pylori)

👉 Reflex line: “Animals: many → Humans: few.”

🦠 Established Human Oncogenic Microbes

• Viruses: only a small, defined group
• Bacterium: Helicobacter pylori
• Causes:
• Gastric adenocarcinoma
• Gastric MALT lymphoma

👉 Memory lock: “H. pylori = Hot stomach cancer.”

🧬 HTLV-1 — ONLY Proven Human Oncogenic Retrovirus

🎯 Identity Lock

• Virus: HTLV-1
• Cancer: Adult T-cell leukemia/lymphoma (ATLL)
• Target cell: CD4+ T cells

👉 “HTLV-1 → Adult T cells → CD4 door.”

🌍 Epidemiology & Transmission

• Endemic regions: Japan, Caribbean, South America, Africa

→ J-CASA

• Global infection: ~15–20 million
• Transmission: Sex, Blood, Breast milk

→ “3 doors: Sex–Blood–Milk”

• Disease risk: only 3–5% develop ATLL
• Latency: 40–60 years

👉 “Few get sick, decades later.”

Features:

• Aggressive CD4⁺ T-cell malignancy
• Generalised lymphadenopathy
• Hepatosplenomegaly
• Skin lesions
• Hypercalcaemia (classic exam clue)

🧪 Viral Integration — Exam Trap

• NO viral oncogene
• NO consistent integration near same proto-oncogene
• Integration is random between patients
• Clonal (identical) within a single tumor-all tumor cells originated from ONE original cell.

👉 “Random entry, clonal crime scene.”

⚠️ KEY ONCOGENIC DRIVER = TAX

🧩 Tax protein Core Functions (3 must-remember jobs)

1. ↑ Viral RNA transcription
2. Reprograms host gene transcription
3. Hijacks growth & survival signaling

👉 “Tax controls virus + host.”

🚀 Pro-Growth & Survival Effects

• Activates PI3K
• ↑ Cyclin D
• ↓ CDK inhibitors
• Forces G1 → S transition
• Activates NF-κB

👉 “Growth ON, brakes OFF, NF-κB ON.”

🧬 Genomic Instability

• Impairs:
• DNA repair
• Cell-cycle checkpoints
• Causes aneuploidy

👉 “Tax breaks DNA police.”

🔄 STEPWISE PATH TO ATLL (Classic Exam Flow)

1. HTLV-1 infects CD4+ T cells
2. Polyclonal T-cell expansion (Tax-driven)
3. Mutation accumulation + genomic instability
4. Persistent TCR signaling + NF-κB activation
5. Emergence of one monoclonal malignant clone

→ Adult T-cell leukemia/lymphoma

👉 Ultra-reflex line:

“Poly → Mutate → Mono → Malignant (TCR + NF-κB ON).”

🧠 FINAL EXAM SNAPSHOT (10-second recall)

• Humans: few oncogenic microbes
• Only oncogenic retrovirus = HTLV-1
• No viral oncogene
• Cancer via Tax-driven signaling + instability
• Long latency, low incidence, monoclonal end

3. Oncogenic DNA Viruses in Humans — The “Big Five”

• In animals, many DNA tumor viruses exist. → Memory: “Animals host many DNA tumor viruses.”
• In humans, five DNA viruses have strong cancer links:

1. HPV (Human papillomavirus)
2. EBV (Epstein–Barr virus)
3. KSHV/HHV-8 (Kaposi sarcoma–associated herpesvirus)
4. Merkel cell polyomavirus
5. HBV (Hepatitis B virus)

→ Memory: “HEK-MH” (HPV, EBV, KSHV, Merkel, HBV).

• This note focuses mainly on HPV, EBV, HBV, plus HCV (an RNA virus grouped with HBV due to shared HCC risk). → Memory: “Focus = HPV + EBV + HBV (+ HCV).”
• KSHV is usually discussed separately with Kaposi sarcoma.
• Merkel cell polyomavirus is linked to Merkel cell carcinoma (rare), and not covered in depth here. → Memory: “Merkel = Minimal (here).”
• HCV is grouped with HBV because both cause chronic liver damage and hepatocellular carcinoma. → Memory: “HCV sneaks in with HBV.”

4. HPV — Human Papillomavirus

4.1 Types and Clinical Syndromes

• There are many HPV types (“scores of types”). → Memory: “HPV = Huge Population of Viruses.”
• Benign skin warts: HPV 1, 2, 4, 7 → Memory: “1-2-4-7 = Warts Heaven.”
• Genital warts (condyloma), low cancer risk: HPV 6, 11 → Memory: “6 & 11 = Sexy but Safe.”
• High-risk oncogenic types: HPV 16, 18 → Memory: “Sweet 16 → Deadly 18.”

4.2 HPV-Associated Cancers

High-risk HPV is linked to:

• Cervical squamous cell carcinoma
• Other anogenital cancers
• At least 20% of oropharyngeal cancers, particularly tonsillar tumors

→ Memory: “HPV = Cervix, Genitals, Tonsils.”

4.3 Viral Oncoproteins: E6 and E7

• Key viral “bad actors”: E6 and E7 → Memory: “E6 kills p53, E7 wrecks RB.”

4.3.1 E6 Actions

• Binds and promotes degradation of p53, the major DNA damage checkpoint protein.
• Upregulates TERT (telomerase) → allows cell immortalization.
• High-risk E6 binds p53 more strongly than low-risk types. → Memory: “Eliminate p53 + Extend telomeres.”

4.3.2 E7 Actions

• Binds RB, releasing E2F, which drives G1→S transition.
• High-risk E7 binds RB more strongly.
• Inactivates p21 and p27 (CDK inhibitors).
• Upregulates cyclin E and cyclin A. → Memory: “Escape RB + Erase inhibitors + Energize cyclins.”

4.4 Genome Status: Benign vs Malignant

• In benign warts, HPV DNA remains episomal (separate from host genome). → Memory: “Episomal = Extra, outside genome.”
• In cancers, HPV DNA tends to integrate into the host genome, often disrupting a viral “brake” gene.
• This leads to overexpression of E6/E7.
• Integration also promotes genomic instability. → Memory: “Integration = Infinite E6/E7.”

4.5 Cancer Hallmarks Driven by HPV

• RB and p53 are switched OFF.
• Cyclin/CDK activity is switched ON.
• Cellular senescence and apoptosis are bypassed.
• Cells show increased proliferation and genomic instability. → Memory: “HPV = Hallmarks Promoted Virally.”

4.6 Proof of Causation and Cofactors

• HPV vaccines prevent cervical cancer, providing powerful causal proof. → Memory: “Vaccine victory = proof.”
• HPV alone is not sufficient:
• Additional host mutations (e.g., RAS) are needed for full transformation. → Memory: “HPV lights the fire, RAS adds fuel.”
• In most women, HPV infection is cleared by the immune system and does not progress to cancer. → Memory: “Strong immunity sweeps HPV out.”
• Highest risk occurs when:
• High-risk HPV infection is combined with HIV co-infection (immunosuppression) → poor viral clearance. → Memory: “HPV + HIV = Deadly Duo.”

HPV — Structure of the Virus (exam reflex)

Core structural facts

• Small, non-enveloped virus
• Icosahedral capsid
• Circular double-stranded DNA (dsDNA) genome
• Size ≈ 55 nm

Capsid

• Made of 72 capsomeres
• Major capsid protein: L1
• Forms the capsid
• Vaccine target (virus-like particles)
• Minor capsid protein: L2
• Assists viral entry & genome delivery

Genome organization

• Early (E) region → regulatory/oncogenic proteins
• E6, E7 (oncoproteins)
• E1, E2 (replication & transcription control)
• Late (L) region → structural proteins
• L1, L2
• Long Control Region (LCR)
• Non-coding
• Controls transcription & replication

Structure → behavior (exam logic)

• No envelope → resistant to drying & detergents
• Replicates in stratified squamous epithelium
• Assembly occurs without cell lysis
• Productive infection in differentiated epithelial layers

Types

• Skin warts → HPV 1, 2, 4, 7
• Genital warts (low risk) → HPV 6, 11
• Oncogenic (high risk) → HPV 16, 18

HPV-associated cancers

• Cervical squamous cell carcinoma
• Other anogenital cancers
• ~20% oropharyngeal cancers (esp. tonsils)

Oncoproteins (core mechanism)

• E6 → p53 degradation + ↑ TERT (telomerase)

→ DNA damage checkpoint OFF + immortalization

• E7 → RB inactivation → E2F release
• ↓ p21, ↓ p27, ↑ cyclin E & A

→ G1→S unchecked

Genome status

• Benign warts → HPV DNA episomal
• Cancer → HPV DNA integrated
• Disrupts viral brake → ↑↑ E6/E7
• Causes genomic instability

Hallmarks driven by HPV

• p53 & RB OFF
• Cyclin/CDK ON
• Apoptosis & senescence bypassed
• High proliferation + instability

Causation & cofactors

• HPV vaccines prevent cervical cancer → causal proof
• HPV alone insufficient → needs host hits (e.g., RAS)
• Most infections cleared by immunity
• Highest risk: High-risk HPV + HIV (poor clearance)

One-line exam lock

High-risk HPV (16,18) causes cancer via E6-mediated p53 loss and E7-mediated RB inactivation, especially after viral genome integration, with risk amplified by immunosuppression (e.g., HIV).

5. EBV — Epstein–Barr Virus

5.1 Basics

• Family: Herpesvirus → Memory: “EBV = Herpes cousin.”
• First tumor linked: Burkitt lymphoma → Memory: “Burkitt’s first love.”

5.2 EBV-Associated Tumors

• Burkitt lymphoma (especially endemic African type)
• Nasopharyngeal carcinoma (NPC) — essentially 100% EBV-associated
• Some T-cell and NK-cell lymphomas
• A subset of gastric carcinomas
• Rare sarcomas, particularly in immunosuppressed patients → Memory: “B, N, T, NK, Stomach, Sarcomas.”
• Endemic Burkitt lymphoma:
• Common in parts of Africa.
• Tumor cells almost always harbor EBV genome. → Memory: “African children, swollen jaws.”
• Sporadic Burkitt lymphoma:
• Occurs worldwide.
• Often EBV-negative, but shares the same key genetic lesion: MYC translocation, typically t(8;14). → Memory: “MYC is the final common pathway.”

5.3 Viral Entry and In Vitro Effects

• Receptor on B cells: CD21 → Memory: “21 = Doorway.”
• In vitro, EBV infection of B cells:
• Causes polyclonal B-cell proliferation.
• Produces immortal lymphoblastoid cell lines. → Memory: “Immortalizer.”

5.4 Oncogenic Viral Proteins

• LMP1 (Latent membrane protein 1):
• Mimics a constitutively active CD40 receptor.
• Activates NF-κB and JAK/STAT pathways → promotes B-cell growth and survival. → Memory: “LMP1 = CD40 stuck ON.”
• EBNA2:
• Upregulates cyclin D and SRC. → Memory: “EBNA2 = Extra Boost (cyclin D & SRC).”
• vIL-10:
• A viral interleukin-10 analogue.
• Suppresses macrophage/monocyte activation of T cells.
• Promotes immune evasion. → Memory: “vIL-10 = Viral Immune Lock.”

5.5 Immune Control and Persistence

• In healthy hosts:
• Cytotoxic T cells destroy proliferating EBV-infected B cells.
• Outcome = asymptomatic infection or infectious mononucleosis. → Memory: “Strong T cells stop spread.”
• EBV persistence:
• Some infected B cells downregulate LMP1 and EBNA2.
• Survive as latently infected memory B cells for life. → Memory: “Hide in memory cells forever.”

5.6 Burkitt Lymphoma Pathogenesis

• In endemic regions:
• Co-infection such as malaria weakens T-cell immunity.
• EBV-infected B cells proliferate more freely.
• A MYC translocation (t(8;14)) arises.
• This leads to Burkitt lymphoma. → Memory: “Malaria weakens guard → MYC lights fire.”

5.7 EBV in Immunosuppressed Hosts

• In AIDS and post-transplant immunosuppression:
• EBV-positive B-cell lymphomas are common.
• Often multiple lesions.
• Early phase: polyclonal, later becomes monoclonal.
• Usually lack MYC translocation.
• Express LMP1 and EBNA2, so they are highly antigenic.
• These lymphomas can regress if T-cell function is restored (e.g., reducing immunosuppressive therapy). → Memory: “Bring T cells back → tumor shrinks.”

5.8 Nasopharyngeal Carcinoma (NPC)

• NPC is almost 100% EBV-associated. → Memory: “Nasopharynx = Always EBV.”
• Endemic in:
• Southern China
• Parts of Africa
• Inuit Arctic populations → Memory: “China, Africa, Arctic.”
• Proof of causation:
• The same EBV integration (clonal) is found in all tumor cells.
• Indicates that EBV infection occurred before tumor expansion. → Memory: “Same viral site = smoking gun.”
• Pathogenesis also depends on:
• Genetic factors
• Environmental factors (e.g., diet, nitrosamines). → Memory: “EBV + Genes + Environment.”
• LMP1 plays a major role in NPC:
• Activates NF-κB
• Increases VEGF → more blood vessels
• Increases metalloproteases → tissue invasion → Memory: “Build blood & break barriers.”
• EBV also contributes to some Hodgkin lymphomas.

6. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) — Liver Cancer

6.1 Overall Impact

• HBV and HCV together account for about 70–85% of hepatocellular carcinoma (HCC) worldwide. → Memory: “Most liver cancers = Hepatitis-driven.”

6.2 Viral Oncogene Status and Integration

• Neither HBV nor HCV carries a classic transforming viral oncogene like HPV E6/E7. → Memory: “No viral oncogenes; cancer comes indirectly.”
• HBV DNA:
• Can integrate into the host genome.
• Integration sites are generally random (no single hot-spot gene). → Memory: “HBV inserts randomly.”

6.3 Major Carcinogenic Mechanism: Chronic Inflammation and Repair

The shared central mechanism:

1. Chronic inflammation of the liver.
2. Persistent cell death and injury.
3. Continuous regeneration (repair loops).
4. Progressive DNA damage and mutations.

→ Memory: “Inflammation → Injury → Instability.”

• This represents an “immune paradox”:
• Immune responses usually protect against pathogens.
• But when inflammation becomes chronic (HBV/HCV, H. pylori), the ongoing immune attack damages host tissue and promotes cancer. → Memory: “Immune fire burns the host.”
• Chronic hepatitis:
• Hepatocytes undergo repeated cycles of injury and regrowth. → Memory: “Stuck in repair loop.”
• During these loops, the microenvironment is rich in:
• Growth factors
• Cytokines
• Chemokines
• Other bioactive mediators supporting survival, remodeling, and angiogenesis. → Memory: “Immune soup feeds tumors.”
• Reactive oxygen species (ROS) generated by inflammation:
• Directly damage DNA → mutations. → Memory: “ROS = Rust on DNA.”

6.4 NF-κB Pathway and Survival

• Chronic inflammatory signals often activate NF-κB in hepatocytes.
• NF-κB activation:
• Prevents apoptosis of damaged cells.
• Allows these cells to keep dividing while accumulating mutations. → Memory: “NF-κB = No cell death.”

6.5 HBV-Specific Factors

• HBx protein:
• An HBV regulatory protein with direct pro-oncogenic functions.
• Activates various transcription factors and signaling pathways.
• May interfere with p53.
• In transgenic mice, HBx alone can induce HCC. → Memory: “HBx hijacks signals + blocks p53.”
• HBV integration:
• Can cause chromosomal rearrangements or deletions.
• These may inactivate tumor suppressor genes. → Memory: “HBV cuts & deletes DNA pages.”

6.6 HCV-Specific Features

• HCV is an RNA virus (does not integrate like HBV), but has a strong link to HCC.
• Key mechanisms:
• Chronic hepatitis with inflammation and repair, similar to HBV.
• HCV core protein can activate growth signaling pathways, further promoting carcinogenesis. → Memory: “HCV = Hidden cancer virus; core = driver.”

7. Helicobacter pylori — The Carcinogenic Bacterium

7.1 Major Cancers Linked

• Gastric adenocarcinoma
• Gastric MALT lymphoma (B-cell) → Memory: “Heartburn → tumor.”
• Historically first recognized for causing peptic ulcers. → Memory: “Ulcers first, cancer later.”
• Important milestone: first bacterium officially designated as a carcinogen. → Memory: “Bug officially a cancer maker.”

7.2 Pathogenesis of Gastric Adenocarcinoma

• Chronic H. pylori–induced gastritis:
• Causes sustained inflammation.
• Leads to increased epithelial proliferation and ROS-mediated DNA damage. → Memory: “Inflammation = cancer fertilizer.”
• Stepwise precancerous cascade:
1. Chronic gastritis
2. Gastric atrophy
3. Intestinal metaplasia
4. Dysplasia
5. Carcinoma → Memory: “G → A → M → D → C (GAMDC).”
• Only about 3% of infected individuals progress to cancer, and this typically takes decades. → Memory: “Only a few after many years.”

7.3 Virulence Factor: CagA

• Certain H. pylori strains carry a pathogenicity island encoding CagA.
• CagA is injected into gastric epithelial cells.
• It mimics growth-factor signaling and disturbs intracellular pathways:
• Promotes uncontrolled cell growth and survival. → Memory: “CagA = Fake Growth Factor.”

7.4 Gastric MALT Lymphoma

• H. pylori is strongly associated with gastric B-cell MALT lymphoma.
• Risk is influenced by:
• Bacterial factors (strain virulence, CagA status, etc.)
• Host genetic factors (e.g., cytokine polymorphisms in IL-1β and TNF). → Memory: “Bug genes + host genes.”
• Immune path to lymphoma:
1. H. pylori stimulates T cells.
2. These T cells provide help to B cells, causing polyclonal B-cell proliferation.
3. Over time, mutations accumulate.
4. A single B-cell clone becomes malignant. → Memory: “T cells push B cells → one clone escapes.”
• Early-stage MALT lymphoma:
• Often regresses when H. pylori is eradicated with antibiotics.
• Because tumor cells depend on ongoing immune (T-cell) signals driven by the infection. → Memory: “Kill bug → shrink tumor.”
• Unique feature:
• MALT lymphoma is “addicted” to immune signaling in its early stages. → Memory: “Cancer addicted to immune talk.”

8. Ultra-Short High-Yield Recap

• HTLV-1
• Retrovirus → ATLL
• Targets CD4+ T cells
• Regions: “J-CASA”
• Oncogenic driver: Tax
• Tax → PI3K↑, cyclin D↑, CDK inhibitors↓, NF-κB ON, genomic instability
• Only 3–5% get ATLL after 40–60 years
• Transmission: Sex, Blood, Milk
• HPV (16, 18)
• High-risk types cause cervix, anogenital, ~20% oropharyngeal cancers
• E6 → kills p53, activates TERT
• E7 → wrecks RB, inhibits p21/p27, upregulates cyclins E/A
• Integration → E6/E7 overdrive + genomic instability
• Vaccines are preventive
• Need extra mutations (e.g., RAS); risk ↑ with HIV
• EBV
• Oncogenic players: LMP1, EBNA2, vIL-10
• Tumors: Burkitt lymphoma, NPC (100%), some T/NK lymphomas, gastric carcinoma, rare sarcomas, some Hodgkin lymphomas
• MYC t(8;14) central in Burkitt
• Immunosuppressed B-cell lymphomas may regress when T-cell function returns
• HBV/HCV
• Account for 70–85% of HCC
• Mechanism: chronic inflammation → injury → regeneration → ROS → mutations, NF-κB ON
• HBx (HBV) activates signals, may inhibit p53; random integration → deletions
• HCV core also drives growth signals
• H. pylori
• Causes gastric adenocarcinoma and gastric MALT lymphoma
• Pathway: Gastritis → Atrophy → Metaplasia → Dysplasia → Carcinoma
• Only ~3% progress over decades
• CagA mimics growth factor signaling
• Early MALT lymphoma can regress with antibiotic eradication of H. pylori

If you want, next I can:

• Turn this into a Google-Docs-ready active recall table
• Convert it into XMind-friendly markdown, or
• Make a pure SBA/MCQ set just from this chapter (step 1 of your 3-step workflow).